| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | AZD6244 | UHNBreast | pan-cancer | AAC | -0.38 | 0.2 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.2 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.37 | 0.2 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.068 | 0.2 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.2 |